3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Recruiting
1
Completed
1
Sponsor Class
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Recurrence
1
Multiple Myeloma
1
Genetic Diseases, Inborn
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Dexamethasone
29
Cyclophosphamide
21
Rituximab
17
Cytarabine
16
Bortezomib
13
Gemcitabine
12
fludarabine
11
Methotrexate
11
Lenalidomide
10
Filgrastim
10
Vincristine
9
Etoposide
9
pomalidomide
8
pembrolizumab
8
Paclitaxel
8
Azacitidine
8
venetoclax
7
carfilzomib
7
Doxorubicin
7
Docetaxel
7
Cyclosporine
7
Calcium Dobesilate
7
Antilymphocyte Serum
7
fludarabine phosphate
6
Topotecan
6
Temozolomide
6
Radiotherapy
6
Peripheral Blood Stem Cell Transplantation
6
Mitoxantrone
6
daratumumab
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Recurrence
×
Clinical Trials, Phase II as Topic
×
Clear all
NCT03683277
2025-02-19
IFM2014-01
Intergroupe Francophone du Myelome
Phase 2
Terminated
26 enrolled